Submit communications under section 505(b) (the act) (21 USC 355 (b) to:
Division of Anesthesia,
Analgesia and Rheumatology Products,
Office of New Drugs, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Silver Spring,
MD 20993
Document Subtype:
N-Notice
Received Date:
October 01 2010, at 12:00 AM Eastern Daylight Time
Single-Ingredient Oral Colchicine Products; Enforcement Action Dates
Details Information
Comments
Related Documents